GPT Healthcare Senior Vice President and Chief Business Development Officer Resigns Due to Personal Reasons

GPT Healthcare Limited has announced the resignation of its Senior Vice President and Chief Business Development Officer, Mr. Debashis Dhar, effective from the close of business hours on April 2, 2026. The resignation was submitted due to personal reasons, marking the departure of a key member of the company's senior management team.

Resignation Details

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about this senior management change in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Dhar served as one of the Senior Management Personnel (SMP) of the company and will cease to hold this designation from the effective date of his resignation.

Parameter	Details
Name of SMP	Mr. Debashis Dhar
Position	Senior Vice President and Chief Business Development Officer
Reason for Change	Resignation due to personal reasons
Effective Date	Close of business hours on April 2, 2026
Documentation	Resignation letter dated April 2, 2026 enclosed

Resignation Letter Highlights

In his resignation letter addressed to the Executive Director, Mr. Dhar expressed gratitude to the promoters and leadership team for their continued trust, encouragement, and guidance throughout his tenure. He acknowledged having the privilege of witnessing the organization's growth and evolution, stating that he felt honored to have contributed to the company's journey in his capacity.

Regulatory Compliance

The announcement was made through a formal communication to the stock exchanges, signed by Ankur Sharma, Company Secretary and Compliance Officer. The disclosure includes all required details under Regulation 30 of the Listing Regulations, ensuring full transparency with stakeholders and regulatory authorities.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.52%	+1.33%	-2.33%	-16.43%	-17.36%	-38.56%

Q3FY26 Financial Performance

The company demonstrated strong revenue momentum with quarterly revenue reaching ₹121.6 Cr compared to ₹104.1 Cr in Q3FY25. However, profitability metrics showed pressure with EBITDA declining 4.38% to ₹22.2 Cr and PAT dropping 23.50% to ₹9.4 Cr. EBITDA margins compressed to 18.20% from 22.23% in the previous year.

Metric:	Q3FY26	Q3FY25	YoY Change
Total Revenue:	₹121.6 Cr	₹104.1 Cr	+16.81%
EBITDA:	₹22.2 Cr	₹23.1 Cr	-4.38%
EBITDA Margin:	18.20%	22.23%	Compression
PAT:	₹9.4 Cr	₹12.1 Cr	-23.50%

Nine-Month Performance Overview

For 9MFY26, the company achieved total revenue of ₹350.5 Cr, representing 12.12% year-on-year growth from ₹312.6 Cr in 9MFY25. Despite revenue growth, EBITDA declined 6.39% to ₹65.1 Cr with margins compressing from 22.26% to 18.58%. PAT for the nine-month period stood at ₹27.6 Cr, down 25.32% from ₹37.0 Cr in the previous year.

Parameter:	9MFY26	9MFY25	Change
Total Revenue:	₹350.5 Cr	₹312.6 Cr	+12.12%
EBITDA:	₹65.1 Cr	₹69.6 Cr	-6.39%
PAT:	₹27.6 Cr	₹37.0 Cr	-25.32%

Operational Highlights and Network Expansion

The company maintained competitive ARPOB at ₹38,797 while achieving 55% occupancy excluding the newly commenced Raipur facility. Including Raipur, overall network occupancy stands at 45%. The company commissioned CTVS (Cardiothoracic and Vascular Surgery) services at ILS-Dum Dum, providing complete cardiac care under one roof. The Raipur facility continues scaling efficiently while the Jamshedpur project progresses as planned.

Management Commentary

Chairman Dr. Om Tantia highlighted the company's disciplined execution and improving operating metrics. He emphasized the completion of over 750+ robotic surgeries at ILS Salt Lake, reinforcing the company's position in advanced minimally invasive care. The payer mix remained predominantly cash and insurance, reflecting revenue quality and financial resilience while serving the aspirational middle-to-high income population.